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Introduction
Staphylococcus aureus has been considered as one of 
the pathogenic bacteria responsible for a wide variety of 
diseases. Such diseases range from slight skin infections 
to critical infections including septicemia (Tokajian 
2014). After the introduction of methicillin in 1959, 
methicillin-resistant S. aureus (MRSA) has transpired 
as a significant hospital-associated pathogen (Tokajian 
2014). The widespread of MRSA and its capability for 
escalating in hospitals and community settings repre-
sent a real threat that stands against infection control 
practices (Tokajian 2014). The epidemiology of MRSA 
differs noticeably worldwide even at regional levels 
(Borg et al. 2007). In comparison with other African, 
southern and eastern Mediterranean countries, Egypt 
showed the highest rates of MRSA occurrence among 
S. aureus clinical isolates (Abdel-Maksoud et al. 2016). 
According to the Antibiotic Resistance Surveillance and 
Control in the Mediterranean Region, more than 50% 
of the S. aureus isolates, obtained from blood cultures 
in Egypt, during a three-year study period (2003–2005), 
were recognized to be methicillin-resistant (Borg et al. 
2007). Poor and problematic healthcare system in the 
majority of African countries, not excluding Egypt, 
inadequate financing, poor provision of properly trained 
healthcare professionals, poverty in infrastructure and 
occasional lack of adequate medications aggravate the 
problem, making the fight of these countries against this 
pathogen a real challenge (Falagas et al. 2013).
Fluoroquinolones have been recognized as promis-
ing and potent antibiotics which inhibit DNA gyrase 
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A b s t r a c t
The widespread of infections caused by methicillin-resistant Staphylococcus aureus (MRSA), has necessitated the search for alternative 
therapies; introduction of new agents being a suggestion. This study compares the in vitro and in vivo activities of zabofloxacin, a novel 
fluoroquinolone, with moxifloxacin, levofloxacin and ciprofloxacin against clinical isolates of MRSA from patients hospitalized in the 
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MIC50 and MIC90 (0.25 and 2 µg/ml, respectively). Time-kill curve analysis revealed a rapid bactericidal activity of zabofloxacin after 6 h 
of incubation with a quinolone-resistant isolate and complete killing when tested against a quinolone-sensitive isolate with inhibition of 
regrowth in both cases. PCR amplification and sequencing of QRDRs in selected strains revealed the following amino acid substitutions: 
Ser-84→Leu in GyrA, Ser-80→Phe in GrlA and Pro-451→Ser in GrlB. The in vivo studies demonstrated that zabofloxacin possessed the most 
potent protective effect against systemic infection in mice (ED50: 29.05 mg/kg) with lowest count in the dissected lungs (3.66 log10 CFU/ml). 
The histopathological examination of lung specimens of mice treated with zabofloxacin displayed least congestion, inflammation, oedema 
and necrosis with clear alveolar spaces and normal vessels. In conclusion, zabofloxacin was proved to possess high in vitro and in vivo 
efficacy encompassing its comparators and could be considered as a possible candidate for the treatment of infections caused by MRSA. 
To our knowledge, this is the first study evaluating the in vitro and in vivo activity of zabofloxacin against Egyptian MRSA clinical isolates.
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and topoisomerase IV resulting in impeding the super-
coiling of the DNA and causing bacterial death (Kocsis 
et al. 2016). The classic fluoroquinolones possess a con-
siderable antimicrobial activity against Gram-negative 
bacteria, but their potency against Gram-positive bac-
teria has been controverted (Park et al. 2006). Therefore, 
research in the field of fluoroquinolones was oriented 
towards potentiating the antimicrobial efficacy against 
Gram-positive cocci, anaerobes and fluoroquinolone-
resistant strains by finding substituents with better 
binding affinity to target enzymes (Kwon et al. 2006). 
Consequently, a number of new agents have been devel-
oped, among which was zabofloxacin (Kocsis et al. 
2016). Zabofloxacin is a novel member in the family 
of fluoroquinolones (Park et al. 2006) with reported 
activity against methicillin-resistant coagulase-nega-
tive staphylococci, Streptococcus pyogenes, Streptococ-
cus pneumoniae and Enterococcus faecalis. Its activity 
against these organisms is regarded to be superior to 
other fluoroquinolones as ciprofloxacin, moxifloxacin, 
and gemifloxacin (Park et al. 2006; Karpiuk and Tyski 
2013). Zabofloxacin is slightly inferior in comparison 
with other fluoroquinolones against Enterobacteriaceae 
family. However, it is effective against the Gram-nega-
tive respiratory bacteria, such as Haemophilus influen-
zae and Moraxella catarrhalis (Karpiuk and Tyski 2013). 
Owing to the double mechanism of binding of zabo-
floxacin to the complex enzyme-DNA, the likelihood 
of the development of bacterial resistance is markedly 
diminished (Karpiuk and Tyski 2013).
The present study compared the in vitro activity of 
zabofloxacin with moxifloxacin, levofloxacin and cip-
rofloxacin against MRSA clinical isolates collected from 
hospitalized patients admitted to the Alexandria Main 
University hospital (AMUH); a tertiary hospital based 
in Alexandria, Egypt, where zabofloxacin has not been 
yet introduced. In addition, the in vivo protective activ-
ity of zabofloxacin and comparator fluoroquinolones 
against systemic infection caused by MRSA clinical 
isolate was evaluated using a mice model.
Experimental
Materials and Methods
Test organisms and bacterial identification. One 
hundred-sixteen clinical isolates of MRSA were collected 
from the routine laboratory of Alexandria Main Univer-
sity Hospital (AMUH) over a six-month period between 
January 2017 to July 2017. The clinical origins of these 
isolates were as follow: bronchoalveolar lavages (n = 66), 
blood (n = 19), urine (n = 16), pus (n = 11), and wound 
swabs (n = 4). As a quality control, a reference strain of 
methicillin-sensitive S. aureus (MSSA; ATCC 25923) 
and a strains of methicillin-resistant S. aureus (MRSA; 
ATCC 43300) strains were included in this study.
The specimens were cultured on Mannitol Salt Agar 
and identified by colony morphology, Gram stain, as 
well as, by biochemical characteristics, which were 
estimated by the commercial test system Dry Spot 
Staphytect Plus (Oxoid, UK). Methicillin resistance 
was confirmed by cefoxitin and oxacillin disc diffu-
sion methods according to the Clinical and Laboratory 
Standards Institute guidelines (CLSI 2013).
Antibiotics. Ciprofloxacin, CIP, (Amryia Pharm. 
Ind., Egypt), levofloxacin, LEV, (Sanofi-Aventis, Ger-
many) and moxifloxacin, MOX, (Alcon, Belgium) were 
purchased from pharmaceutical markets. Zabofloxacin 
powder, ZAB, was provided by the courtesy of Dong-
wha Pharm. Co., Ltd. (Seoul, Korea).
Laboratory animals. Five-week-old male Swiss 
albino mice (body weight, 17–21 g) were purchased 
from Theodor Bilharz Research Institute, Giza, Egypt. 
All mouse experiments were performed in accordance 
with the ethical guidelines of the Institutional Animal 
Care and Use Committee, Faculty of Pharmacy, Ale-
xandria University (ACUC Project # ACUC18/28). 
Mice were housed in animal rooms maintained at 
23 ± 2°C with 50 ± 20% relative humidity.
Antimicrobial susceptibility testing. Minimum 
inhibitory concentrations (MICs) were determined by 
the microtiter broth dilution method according to the 
guidelines of CLSI (2012). Microtiter plates containing 
5.0 × 105 CFU/ml were incubated with serial dilutions of 
each antibiotic in Mueller-Hinton broth (Oxoid, UK) 
at 35°C for 18 h, and the lowest concentration of the 
antibiotic that prevented visible growth was considered 
as the MIC.
Time-kill analysis. The time-kill studies were perfor-
med following CLSI M26-A guidelines (1999). Two iso- 
lates, one resistant and one susceptible to the four tested 
fluoroquinolones, named S13 and S15 respectively, were 
selected for this analysis. The bacterial cultures in Muller- 
Hinton broth (Oxoid, UK) were diluted to reach an appro- 
ximate count of 105 to 106 CFU/ml and preincu bated for 
2 h. Then, ZAB, MOX, LEV and CIP were added to the 
cultures at concentrations of 0.5, 1, 2, and 4 MIC. The 
bacterial count was determined after 0, 3, 6 and 24 h of 
incubation with the antibiotics tested by culturing the 
bacteria on Muller-Hinton agar (Oxoid) at 37°C for 18 h 
following serial dilution. The anti bio tic was considered 
as bactericidal at a concentration, which decreased the 
control count by 3 log CFU/ml (99.9%) at specified time 
intervals. The procedure was performed in triplicates 
and a graph of the log CFU/ml was then plotted against 
time with calculation of standard deviation.
Quinolone resistance-determining region (QRDR) 
sequence analysis. PCR was used to amplify the QRDRs 
of the gyrA, parC and parE genes using extracted 
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genomic DNA of the strains tested as a template and 
the previously described primer pairs and cycling con-
ditions (Pan et al. 1996). To determine alterations in 
the DNA gyrase or topoisomerase IV, selected PCR 
products were purified using Zymo ResearchTM DNA 
Purification Kit and then sequenced using a system 
from LGC Co. Ltd. (Germany).
Determination of ED50. To determine and to com-
pare the in vivo efficacy of ZAB to other fluoroquinolo-
nes in systemic infection murine model, four groups of 
four mice were challenged intraperitoneally with 0.2 ml 
of bacterial suspension adjusted with 5% gastric mucin 
(Oxoid, UK) in 0.9% NaCl solution at a dose 100 times 
higher than the minimal lethal dose. The challenge 
inoculum was sufficient to kill 100% of the untreated 
control mice, which died within 48 h after infection. An 
aliquot of 0.2 ml of each of ZAB, MOX, LEV and CIP 
was administrated twice orally to mice at 1 h and 4 h 
post infection. Four dose levels were used: 0.63, 2.5, 10 
and 40 mg/kg of body weight for each fluoroquinolone. 
Mortality was recorded for seven days and the effective 
dose needed to protect 50% of the mice (ED50) was 
calculated by the method of Miller and Tainter with 
modifications (Randhawa 2009) from the survival rates 
on day 7 post infection.
Bacteriological and histopathological examina-
tions. Twenty-five mice were allocated into five treat-
ment groups: ZAB, MOX, LEV, CIP and normal saline 
(control). The doses of the antibiotics were adjusted 
to 10 mg/kg of body weight and injected intraperito-
neally into mice twice daily beginning 24 h after infec-
tion. Mice were sacrificed by cervical dislocation on 
day 3 (12 h after the fourth administration). For bacte-
riological count, the lungs (n = 4 for each group) were 
dissected under aseptic conditions, suspended in 0.9% 
NaCl solution and homogenized. Serial dilutions were 
performed and bacterial count in homogenized lung 
was determined. Lung tissue for histological examina-
tion (n = 2 for each group) was fixed in 10% buffered 
formalin then stained with hematoxylin-eosin. Histo-
pathological evaluation was done by an investigator 
who was blinded to the sample origin.
Results
In vitro activity. The microtiter broth dilution 
MICs were determined for 116 MRSA clinical isolates 
(Table  I). The strains showed the highest percentage 
of susceptibility to zabofloxacin (61.2%) among the 
fluoro quinolones tested. Comparing the MIC50 and 
MIC90, ZAB showed the highest potency with values 
of 0.25 and 2 µg/ml, respectively. Moxifloxacin followed 
ZAB in activity (MIC50 0.5 µg/ml, MIC90 8 µg/ml), then 
LEV (MIC50 4 µg/ml, MIC90 16 µg/ml) and the least 
effective was CIP (MIC50 8 µg/ml, MIC90 64 µg/ml). The 
distribution of MICs values for the four fluoroquinolo-
nes are shown in Table II. The lowest MIC range among 
Zabofloxacin 0.03 – 4 0.25 2 61.2 0.9 37.9
Moxifloxacin 0.06 – 16 0.5 8 50.9 8.6 40.5
Levofloxacin 0.125 – 64 4 16 46.5 0.9 52.6
Ciprofloxacin 0.125 – > 64 8 64 42.3 1.7 56
Table I
In vitro activity of zabofloxacin, moxifloxacin, levofloxacin and ciprofloxacin against 116 MRSA
clinical isolates.
* MIC50 and MIC90, MICs (μg/ml) for 50% and 90% of isolates tested, respectively.
Antimicrobial
agent
MIC (µg/ml) %
Susceptible
%
Intermediate
%
ResistantMIC range MIC50* MIC90*
Zabofloxacin 10 17 25 12 7 1 32 12 0 0 0 0 0
Moxifloxacin 0 2 7 35 15 10 11 21 13 2 0 0 0
Levofloxacin 0 0 10 33 11 0 1 8 22 29 0 2 0
Ciprofloxacin 0 0 4 18 19 8 2 4 11 19 14 14 3a
Table II
MIC distribution of zabofloxacin, moxifloxacin, levofloxacin and ciprofloxacin determined by broth microdilution method
for 116 MRSA isolates.
Bold figures indicate CLSI breakpoints applied for resistant isolates; zabofloxacin and moxifloxacin: 2 µg/ml, levofloxacin and ciprofloxacin: 4 μg/ml.
a MIC for these isolates was greater than or equal to the indicated value.
MIC (µg/ml)Antimicrobial
agent 0.03 > 6464321684210.50.250.1250.06
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the tested fluoroquinolones was displayed by ZAB 
(0.03 – 4 µg/ml). A comparable range (0.06 – 16 µg/ml) 
was obtained by MOX while old generation fluoro-
quinolones, LEV and CIP, had a much higher range 
(0.125 – >64 µg/ml). In the presence of omeprazole, an 
efflux pump inhibitor (Vidaillac et al. 2007), the ZAB 
MIC values of all tested isolates remained unaffected 
(data not shown).
The bactericidal activity of the fluoroquinolones tested 
against MRSA was compared by time-kill analysis. As 
illustrated in figure 1A–D, ZAB and MOX showed a com- 
parable rapid bactericidal activity with a  decrease in 
the viable count by ≥ 3 log10 CFU/ml after 6 h of contact 
when tested at the concentrations of 2 and 4 MIC against 
the fluoroquinolone-resistant clinical strain S13 (Fig. 1A 
and 1B). Against the fluoroquinolone-sensitive strain, S15, 
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complete killing was achieved at 6 h when ZAB was used 
at a concentration of 2 MIC and at a concentration of 
4 MIC when MOX was used (Fig. 2A and 2B). Regrowth 
of both isolates was completely inhibited by ZAB. Older 
classes fluoroquinolones, LEV and CIP, exhibited an 
inferior pattern of bactericidal activity (Fig. 2A–D).
Fig. 1. Bactericidal activities of (A) zabofloxacin, (B) moxifloxacin, (C) levofloxacin and (D) ciprofloxacin against
fluoroquinolone-resistant MRSA clinical isolate S13. Blue line, 0.5 MIC; red line, 1 MIC; green line, 2 MIC; purple line, 4 MIC.
Data points are geometric means with error bars being one standard deviation of replicate experiments (n = 3).
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Analysis of QRDRs in selected MRSA strains. PCR 
amplification of QRDR sequences of the gyrA, parC 
and parE genes were performed for fluoroquinolone-
resistant isolates. Seven isolates showing different resist-
ance patterns were selected for sequencing analysis to 
detect mutations in DNA gyrase and topoisomerase IV 
as shown in Table III. The detected mutations revealed 
the following amino acid substitutions: Ser-84→Leu in 
GyrA, Ser-80→Phe in GrlA and Pro-451→Ser in GrlB. 
Clinical isolates displaying resistance to ZAB had three 
mutations in the QRDRs of the gyrA, parC and parE 
genes, while isolates resistant to other fluoroquinolo-
nes, but not to ZAB, displayed a single or double point 
mutations.
In vivo activity. The protective efficacy of ZAB 
against systemic infection in mice was compared with 
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those of MOX, LEV and CIP (Table  IV). Zabofloxa-
cin exerted the most potent protective activity (MIC: 
0.06 µg/ml; ED50: 29.05 mg/kg) followed by MOX 
(MIC: 0.06 µg/ml; ED50: 38.69 mg/kg), while LEV and 
CIP required a dose of more than 40 mg/kg to elicit 
a  protective activity against the systemic infection 
(Table  IV). These in vivo results were in accordance 
with the in vitro MICs values.
The mice group treated with ZAB showed the low-
est count in the dissected lungs (3.66 log10 CFU/ml), 
Fig. 2. Bactericidal activities of (A) zabofloxacin, (B) moxifloxacin, (C) levofloxacin and (D) ciprofloxacin against
fluoroquinolone-sensitive MRSA clinical isolate S15. Blue line, 0.5 MIC; red line, 1 MIC; green line, 2 MIC; purple line, 4 MIC.
Data points are geometric means with error bars being one standard deviation of replicate experiments (n = 3).
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S37 4 8 32 64 S84Lb S80Fc P451Sd
S30 2 8 16 64 S84L S80F P451S
S5 2 4 16 64 S84L S80F P451S
S3 2 8 32 64 S84L S80F P451S
S11 0.125 0.25 8 32 S84L None P451S
S38 0.25 0.25 8 16 None S80F None
S22 0.03 0.25 4 8 None S80F None
Table III
MICs of zabofloxacin, moxifloxacin, levofloxacin and ciprofloxacin for selected 7 clinical MRSA 
isolates with detected mutations in QRDRs.
a ZAB: zabofloxacin, MOX: moxifloxacin, LEV: levofloxacin and CIP: ciprofloxacin.
b Serine → Leucine, c Serine → Phenylalanine, d Proline → Serine.
Strain
No.
MIC (µg/ml) Detected Mutation in QRDRs
ZABa MOX LEV CIP gyrA parC parE
 Zabofloxacin  0.06 3.66 29.05
 Moxifloxacin  0.06  4.31 38.69
 Levofloxacin  8 4.01 > 40.00
 Ciprofloxacin 16 4.24 > 40.00
Table IV
In vivo activities of zabofloxacin, moxifloxacin, levofloxacin and ciprofloxacin against mice infected
with MRSA S19 clinical isolate.
a Each antimicrobial agent was administrated twice orally at 1 and 4 h post infection.
b Count in control group receiving saline was log10 5.5 CFU/ml.
c ED50: median effective dose needed to protect 50% of the mice.
Microorganism inoculum
(CFU/mouse)
Antimicrobial
agenta
MIC
(µg/ml)
Count in dissected lungs
log10 (CFU/ml)b
ED50c
(mg/kg)
Methicillin-resistant
S. aureus clinical isolate S19
 0 (40%)
Congestion +1 (20%) +1 (60%) +2 (80%) +3 (60%)
 +2 (40%) +2 (40%) +1 (20%) +1 (40%)
 0 (40%)
Inflammation +1 (20%) +1 (60%) +2 (80%) +3 (60%)
 +2 (40%) +2 (40%) +1 (20%) +1 (40%)
 0 (40%)
Edema +1 (20%) +1 (60%) +2 (80%) +3 (60%)
 +2 (40%) +2 (40%) +1 (20%) +1 (40%)
 0 (40%)
Necrosis +1 (20%) +1 (60%) +2 (80%) +3 (60%)
 +2 (40%) +2 (40%) +1 (20%) +1 (40%)
Table V
Scoring of detected congestion, inflammation, oedema and necro-
sis in lung tissues of mice groups infected with MRSA clinical iso-
late S19 and treated with zabofloxacin, moxifloxacin, levofloxacin 
and ciprofloxacin at a dose of 20 mg/kg of body weight/day.
a Randomly selected sections blindly scored with a score applied
 to review of a whole lung section, scored at X10 magnification.
b ZAB: Zabofloxacin, MOX: moxifloxacin, LEV: levofloxacin
 and CIP: ciprofloxacin.
Histological
observationa
(Score 0–3)
ZABb MOX LEV CIP
when compared to other tested fluoroquinolones or to 
the control receiving saline (Table  IV). These results 
again agreed with the in vitro time-kill curve findings in 
which ZAB showed the highest bactericidal activity as 
compared to the fluoroquinolones under investigation 
(Fig. 1A–D and Fig. 2A–D).
The histopathological examination of lung tissue 
sections obtained from CIP-treated mice group showed 
obvious features of acute bronchopneumonia almost 
the same as those in the untreated control with marked 
congestion, oedema, inflammatory infiltration, necro-
sis with accumulation of necro-inflammatory exudate 
within the lumen of bronchioles (Fig. 3). The lungs of 
ZAB-treated mice group revealed very mild conges-
tion and inflammation with scarce inflammatory cells 
in the interstitial spaces. The mice group treated with 
MOX and LEV displayed moderate interstitial inflam-
mation, moderate congestion and oedema (Fig. 3). 
Figure 4 demonstrates a patent alveolus dissected from 
ZAB-treated mice group, showing clear alveolar spaces 
and normal vessels and bronchioles lined by a layer of 
pneumocytes. The degree of congestion, inflammation, 
oedema and necrosis was scored using a scoring system 
adapted from Dubin and Kolls (2007) and summarized 
in Table V. Mice groups infected with MRSA clinical 
Zabofloxacin activity against MRSA1 67
isolate S19 and treated with ZAB at an adjusted dose 
of 20 mg/kg of body weight/day, displayed best scores 
with least detected congestion, inflammation, oedema 
and necrosis followed by MOX, then LEV and finally 
CIP, all administrated at same dose regimen.
Discussion
Zabofloxacin is a novel fluoroquinolone recently ap- 
pro ved and launched in South Korea (Kocsis and Szabo 
2016) with reported potent in vitro and in vivo activities 
Fig. 3. Lung tissue sections dissected from mice infected with MRSA clinical isolate and treated with (A) zabofloxacin 
showing very mild congestion (arrow) and inflammation with scarce inflammatory cells in the interstitial spaces; (B) moxi-
floxacin showing moderate congestion with ectatic vessels (arrow) and moderate interstitial inflammation; (C) levofloxacin 
showing moderate inflammation, congestion and oedema, with a dilated lymphatic vessel (arrow); and (D) ciprofloxacin 
showing bronchopneumonic changes with marked congestion, oedema, inflammatory infiltration and necrosis, with accu-
mulation of necro-inflammatory exudate within the lumen of bronchioles (arrow) (H&E x400).
Fig. 4. (A, × 100) cross section of lung tissue dissected from mice treated with zabofloxacin showing patent alveoli,
(B, × 400) clear alveolar spaces and normal vessels, the bronchioles are lined by a layer of pneumocytes (arrow).
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against pathogens responsible for respiratory tract and 
uncomplicated skin infections such as S. pneumoniae, 
H. inﬂuenzae, M. catarrhalis and S. aureus (Kwon et al. 
2006; Park et al. 2006). This fluoroquinolone targets 
DNA gyrase and topoisomerase IV, and due to its dou-
ble mechanism of binding to the DNA-enzyme complex, 
mutations in both proteins are required for the develop-
ment of high-level of resistance (Park et al. 2010). This 
agent has not been yet introduced to Egyptian health-
care facilities, including AMUH, a  tertiary hospital 
with a heavy patient turnover and a significantly high 
prevalence rate (71%) of MRSA emerging as a noso-
comial pathogen in its different departments (Sadaka 
et al. 2009). Therefore, the present study was designed to 
evaluate and to compare the in vitro and in vivo activity 
of ZAB against MRSA clinical isolates to older fluoro-
quinolones available on the Egyptian market.
The MIC results showed that ZAB was 4, 8 and 
32-fold more active than MOX, LEV and CIP, respec-
tively (Tables I and II). Among the 116 tested MRSA 
isolates, 61.2% showed susceptibility to ZAB, the high-
est rate obtained among comparators. The MIC50 and 
MIC90 of ZAB were 0.25 and 2 µg/ml, respectively. 
These values were lower than that reported by Kwon 
et al. (2006) and Park et al. (2006) for MRSA isolates; 
probably due to lack of exposure of Egyptian isolates to 
this new antibiotic. In addition, ZAB exhibited a rapid 
bactericidal activity with a decrease in the viable count 
by ≥ 3 log10 CFU/ml after 6 h of contact when tested 
against a fluoroquinolone-resistant isolate and complete 
killing when tested against a fluoroquinolone-sensi-
tive strain with inhibition of regrowth in both cases 
(Fig. 1A–D and 2A–D). Similar rapid bactericidal activ-
ity was reported by Park et al. (2016), when ZAB was 
tested against clinical isolates of S. pneumoniae.
In S. aureus, topoisomerase IV and the A subunit of 
the DNA gyrase are the primary targets for quinolones 
(Sierra et al. 2002; Karpiuk and Tyski 2013; Fernandes 
and Martens 2017); consequently, the gyrA, parC and 
parE genes were screened for mutations in seven iso-
lates showing different patterns of quinolone resistance. 
Isolates displaying resistance to ZAB (MIC: 2–4 µg/ml) 
were found to have their amino acids altered in posi-
tions: Ser84 in GyrA, Ser80 in ParC and Pro451 in ParE. 
Mutations at Ser84 in GyrA, Ser80 in ParC (Yun et al. 
2005) and Pro451 in ParE (Hannachi-M’Zali et al. 2002) 
were reported to be associated with a high-level of qui-
nolone resistance in S. aureus. A single point mutation 
or double point mutation were not able to elicit a con-
siderable increase in MIC values of ZAB (Table  III). 
Park et al. (2016) reported previously that multiple 
mutations are required to produce significant elevations 
in MIC values of ZAB against S. pneumoniae isolates. 
Dual targeting and high susceptibility are desirable 
features in ZAB underlying its importance as a pos-
sible candidate for the treatment of infections caused 
by MRSA. The association of efflux mechanism with 
elevated MICs values has been reported for CIP and 
MOX (Kaatz et al. 2002) while ZAB was shown to be 
a poor efflux substrate (Park et al. 2016), similar finding 
was obtained in the present study suggesting that ZAB 
is a poor substrate for NorA efflux pump.
The in vivo studies demonstrated that ZAB pos-
sessed the most potent protective effect against systemic 
infection caused by a MRSA strain isolated from bron-
choalveolar lavage (Table  IV), similar findings being 
reported by Kwon et al. (2006) and Park et al. (2006). 
The histopathological examination of lung specimens 
of mice infected with MRSA isolate and treated with 
ZAB displayed least congestion, inflammation, oedema 
and necrosis (Table V; Fig. 3); the examined alveoli dis-
played clear alveolar spaces and normal vessels (Fig. 4).
In conclusion, ZAB, a new fluoroquinolone not yet 
introduced to the Egyptian market, was proved to pos-
sess high in vitro and in vivo potency encompassing 
its comparators and might be regarded as an effective 
treatment option for infections caused by MRSA. The 
clinical usefulness of ZAB needs further establishment 
and confirmation in studies with larger number of iso-
lates. To our knowledge, this is the first study evaluat-
ing the in vitro and in vivo activities of ZAB against 
Egyptian MRSA clinical isolates.
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